Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Sulfonamides Stories

2013-05-30 12:27:02

Most Survey Participants Would Recommend Joining a Study to Others TITUSVILLE, N.J., May 30, 2013 /PRNewswire/ -- A survey of a segment of clinical trial participants from the GRACE (Gender, Race And Clinical Experience) trial, the largest-ever study of treatment-experienced adult women with HIV to examine gender differences in response to HIV therapy, found that after taking part in the study, 96 percent of survey responders would recommend participation in a clinical trial to...

2013-04-30 08:34:46

-- TMC310911 is Third Product in Growing Ascletis Pipeline of Infectious Disease and Cancer Therapeutics -- HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/ -- Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in...

2013-04-08 04:20:44

BOSTON, April 8, 2013 /PRNewswire/ -- scPharmaceuticals LLC today announced that it has entered into a strategic partnership and product development agreement with Sensile Medical Holding AG of Zug, Switzerland to develop an innovative new therapeutic option for patients with heart failure. The terms of the agreement were not disclosed. The drug-device combination uses the Sensile SenseCore technology in a wearable minipump that delivers the pharmaceutical drug product under the skin using...

Common Lung Blood Pressure Drug May Damage The Heart
2013-01-22 09:02:22

April Flowers for redOrbit.com - Your Universe Online A new study led by the Faculty of Medicine & Dentistry at the University of Alberta significantly improves understanding of how widely used drugs in pulmonary arterial hypertension (PAH) affect the heart health of patients who use them. The findings of this study, published in a recent issue of Circulation Research, a journal of the American Heart Association, reveal that the medications most often prescribed for PAH could block...

2013-01-22 08:31:17

MADISON, Tenn., Jan. 22, 2013 /PRNewswire/ -- All across America, independent pharmacies and healthcare providers are on the frontlines of pain relief. Consumers and patients rely on the advice and expertise they receive from professionals on the ground locally to control pain and inflammation related to arthritis, muscle strain, joint and back injury, fibromyalgia, plantar fasciitis, headaches, menstrual cramps and more. Given the following facts, retailers and health practitioners bear a...

2013-01-16 04:21:24

CORK, Ireland, January 16, 2013 /PRNewswire/ -- In the news release, "European Commission Approves PREZISTA® (darunavir) 800 mg Tablet Once a Day Reducing the Number of Pills Taken by People Living With HIV" issued on 16 Jan 2013 08:00 GMT, by Janssen R&D Ireland over PR Newswire, please be advised that the first note following paragraph three has been corrected to read "i. ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1...

2013-01-16 04:21:12

CORK, Ireland, January 16, 2013 /PRNewswire/ -- Janssen R&D Ireland announced today that the European Commission (EC) has approved a new PREZISTA(R) (darunavir) 800mg tablet allowing people living with HIV to take one darunavir tablet once a day. Darunavir is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced and treatment-naive patients with no darunavir resistance-associated...

2012-11-29 08:30:07

RARITAN, N.J., Nov. 29, 2012 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced their intention not to enforce the patents they own and control on the antiretroviral (ARV) drug darunavir provided the darunavir product is medically acceptable and is used only in resource-limited settings.(1) This announcement is intended to assure generic manufacturers that they may manufacture high quality darunavir product used in SSA and the LDCs without a concern...

2012-11-09 16:24:26

TITUSVILLE, N.J., Nov. 9, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg tablet of PREZISTA(®) (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. PREZISTA(®) is always taken with and at the same time as...

2012-10-25 11:25:23

BEERSE, Belgium, October 25, 2012 /PRNewswire/ -- Janssen-Cilag International announced today that the European Commission (EC) has approved a 100mg/ml oral suspension of PREZISTA(R) (darunavir), and the use of darunavir co-administered with low dose ritonavir, for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART)-experienced paediatric patients age 3 years and above, weighing at least 15 kg body weight. It must be taken in...